Status:
UNKNOWN
Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
Multiple Sclerosis (MS) is a chronic, autoimmune, neurodegenerative disease; clinical events are mainly attributed to myelin destruction and inflammatory of the central nervous system. The diagnosis ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Major subject (≥18 years old)
- Suffering from relapsing-remitting MS (RRMS)
- Supported in a neurology department at Strasbourg or Nancy University Hospital between 10/01/2018 and 11/31/2020.
- Treated with ocrelizumab 600mg every 6 months during the period from 01/10/2018 to 01/05/2020.
- Have had an M0, M3 / M6 and M12 MRI after initiation of treatment.
- Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research
- Exclusion criteria:
- Subject having expressed opposition to participating in the study
- Primary progressive multiple sclerosis (MS-PP), secondarily progressive (MS-SP)
- Subject not meeting all the inclusion criteria
- Impossibility of providing the subject with enlightened information (difficulties in understanding the subject, etc.)
- Subjects under safeguard of justice
- Subject under guardianship or guardianship
Exclusion
Key Trial Info
Start Date :
November 13 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 13 2021
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04838015
Start Date
November 13 2020
End Date
November 13 2021
Last Update
April 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hautepierre Clinical Investigation Center - Strasbourg University Hospitals
Strasbourg, France, 67091